Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study.

Labreche K, Daniau M, Sud A, Law PJ, Royer-Perron L, Holroyd A, Broderick P, Went M, Benazra M, Ahle G, Soubeyran P, Taillandier L, Chinot OL, Casasnovas O, Bay JO, Jardin F, Oberic L, Fabbro M, Damaj G, Brion A, Mokhtari K, Philippe C, Sanson M, Houillier C, Soussain C, Hoang-Xuan K, Houlston RS, Alentorn A; LOC Network.

Neuro Oncol. 2019 May 17. pii: noz088. doi: 10.1093/neuonc/noz088. [Epub ahead of print]

PMID:
31102405
2.

[Use of the PELICAN software for the creation and export of standardized pathology reports in central nervous system tumors: Example of meningiomas].

Yguel C, Clauzon D, Lacomme S, Lomazzi S, Lardenois E, Pouget C, Taillandier L, Rech F, Rigau V, Vignaud JM, Bauchet L, Gauchotte G.

Ann Pathol. 2019 Mar 7. pii: S0242-6498(19)30032-X. doi: 10.1016/j.annpat.2019.01.016. [Epub ahead of print] French.

PMID:
30853495
3.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma.

J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20.

PMID:
30785830
4.

[Development and deployment of a standardized pathology report in lung cancer, basing on a data management software: The PELICAN software].

Yguel C, Clauzon D, Lacomme S, Siat J, Lomazzi S, Lardenois E, Taillandier L, Vignaud JM, Gauchotte G.

Ann Pathol. 2019 Apr;39(2):87-99. doi: 10.1016/j.annpat.2018.12.001. Epub 2019 Feb 6. French.

PMID:
30736988
5.

Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.

Fabbro-Peray P, Zouaoui S, Darlix A, Fabbro M, Pallud J, Rigau V, Mathieu-Daude H, Bessaoud F, Bauchet F, Riondel A, Sorbets E, Charissoux M, Amelot A, Mandonnet E, Figarella-Branger D, Duffau H, Tretarre B, Taillandier L, Bauchet L.

J Neurooncol. 2019 Mar;142(1):91-101. doi: 10.1007/s11060-018-03065-z. Epub 2018 Dec 6.

6.

Extent of Resection and Residual Tumor Thresholds for Postoperative Total Seizure Freedom in Epileptic Adult Patients Harboring a Supratentorial Diffuse Low-Grade Glioma.

Still MEH, Roux A, Huberfeld G, Bauchet L, Baron MH, Fontaine D, Blonski M, Mandonnet E, Guillevin R, Guyotat J, Taillandier L, Capelle L, Duffau H, Pallud J.

Neurosurgery. 2019 Aug 1;85(2):E332-E340. doi: 10.1093/neuros/nyy481.

PMID:
30395304
7.

Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy.

Abdallah MB, Blonski M, Wantz-Mezieres S, Gaudeau Y, Taillandier L, Moureaux JM, Darlix A, de Champfleur NM, Duffau H.

IEEE J Biomed Health Inform. 2019 Jan;23(1):38-46. doi: 10.1109/JBHI.2018.2834159. Epub 2018 May 7.

PMID:
29993901
8.

Relevance of two manual tumour volume estimation methods for diffuse low-grade gliomas.

Ben Abdallah M, Blonski M, Wantz-Mézières S, Gaudeau Y, Taillandier L, Moureaux JM.

Healthc Technol Lett. 2018 Jan 26;5(1):13-17. doi: 10.1049/htl.2017.0013. eCollection 2018 Feb.

9.

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY.

Oncologist. 2018 May;23(5):524-e44. doi: 10.1634/theoncologist.2017-0689. Epub 2018 Feb 22.

10.

A high 18F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas.

Isal S, Gauchotte G, Rech F, Blonski M, Planel S, Chawki MB, Karcher G, Marie PY, Taillandier L, Verger A.

Br J Radiol. 2018 Apr;91(1084):20170803. doi: 10.1259/bjr.20170803. Epub 2018 Jan 12.

11.

[Proposal of screening for diffuse low-grade gliomas in the population from 20 to 40years].

Mandonnet E, Taillandier L, Duffau H.

Presse Med. 2017 Oct;46(10):911-920. doi: 10.1016/j.lpm.2017.07.005. Epub 2017 Sep 18. French.

PMID:
28927746
12.

[Hypofractionated stereotactic radiotherapy for brain metastasis: Benefit of additional whole brain radiotherapy?]

Royer P, Salleron J, Vogin G, Taillandier L, Clément-Duchêne C, Klein O, Faivre JC, Peiffert D, Bernier V.

Cancer Radiother. 2017 Dec;21(8):731-740. doi: 10.1016/j.canrad.2017.02.005. Epub 2017 Jul 12. French.

PMID:
28711413
13.

Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment.

Darmon I, Morisse MC, Coutte A, Blonski M, Le Rhun E, Taillandier L, Roufai DB, Desenclos C, Trudel S, Faivre JC, Blanchard N, Chauffert B, Boone M.

J Cancer. 2017 May 12;8(8):1417-1424. doi: 10.7150/jca.18339. eCollection 2017.

14.

[Recommendations for the organ donation from patients with brain or medullary primitive tumors on behalf of the Association of the Neuro-oncologists of French Expression (ANOCEF) and the Club of Neuro-oncology of the French Society of Neurosurgery].

Frappaz D, Le Rhun E, Dagain A, Averland B, Bauchet L, Faure A, Guillaume C, Zouaoui S, Provot F, Vachiery F, Taillandier L, Hoang-Xuan K.

Bull Cancer. 2017 Sep;104(9):771-788. doi: 10.1016/j.bulcan.2017.02.007. Epub 2017 May 23. Review. French.

PMID:
28549594
15.

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.

Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assié G, Raverot G.

Eur J Endocrinol. 2017 Jun;176(6):769-777. doi: 10.1530/EJE-16-0979.

PMID:
28432119
16.

Interactions between glioma and pregnancy: insight from a 52-case multicenter series.

Peeters S, Pagès M, Gauchotte G, Miquel C, Cartalat-Carel S, Guillamo JS, Capelle L, Delattre JY, Beauchesne P, Debouverie M, Fontaine D, Jouanneau E, Stecken J, Menei P, De Witte O, Colin P, Frappaz D, Lesimple T, Bauchet L, Lopes M, Bozec L, Moyal E, Deroulers C, Varlet P, Zanello M, Chretien F, Oppenheim C, Duffau H, Taillandier L, Pallud J.

J Neurosurg. 2018 Jan;128(1):3-13. doi: 10.3171/2016.10.JNS16710. Epub 2017 Mar 3.

PMID:
28298039
17.

Statistical evaluation of manual segmentation of a diffuse low-grade glioma MRI dataset.

Ben Abdallah M, Blonski M, Wantz-Mezieres S, Gaudeau Y, Taillandier L, Moureaux JM.

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:4403-4406. doi: 10.1109/EMBC.2016.7591703.

PMID:
28269254
18.

Predictive models for diffuse low-grade glioma patients under chemotherapy.

Ben Abdallah M, Blonski M, Wantz-Mezieres S, Gaudeau Y, Taillandier L, Moureaux JM.

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:4357-4360. doi: 10.1109/EMBC.2016.7591692.

PMID:
28269243
19.

The etiopathogenesis of diffuse low-grade gliomas.

Darlix A, Gozé C, Rigau V, Bauchet L, Taillandier L, Duffau H.

Crit Rev Oncol Hematol. 2017 Jan;109:51-62. doi: 10.1016/j.critrevonc.2016.11.014. Epub 2016 Nov 27. Review.

PMID:
28010898
20.

Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.

Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K.

Neuro Oncol. 2017 Mar 1;19(3):422-429. doi: 10.1093/neuonc/now238.

21.

Erratum to: Epidemiology for primary brain tumors: a nationwide population-based study.

Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, Trétarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L.

J Neurooncol. 2017 Feb;131(3):547. doi: 10.1007/s11060-016-2340-5. No abstract available.

PMID:
27957669
22.

Epidemiology for primary brain tumors: a nationwide population-based study.

Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, Trétarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L.

J Neurooncol. 2017 Feb;131(3):525-546. doi: 10.1007/s11060-016-2318-3. Epub 2016 Nov 16. Erratum in: J Neurooncol. 2017 Feb;131(3):547.

PMID:
27853959
23.

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.

Paquette B, Vernerey D, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O, Anota A, Bonnetain F.

Cancer Med. 2016 Aug;5(8):1753-64. doi: 10.1002/cam4.734. Epub 2016 Jun 1.

24.

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R.

Neuro Oncol. 2016 Sep;18(9):1297-303. doi: 10.1093/neuonc/now033. Epub 2016 Mar 6.

25.

[Systemic therapies administration for adult patients in neuro-oncology: The standards of the Association of the neuro-oncologists of French expression (ANOCEF)].

Simon N, Vasseur M, Chauffert B, Taillandier L, Le Rhun E.

Bull Cancer. 2016 Apr;103(4):400-1. doi: 10.1016/j.bulcan.2016.01.011. Epub 2016 Feb 10. French. No abstract available.

PMID:
26874975
26.

A Probabilistic Atlas of Diffuse WHO Grade II Glioma Locations in the Brain.

Parisot S, Darlix A, Baumann C, Zouaoui S, Yordanova Y, Blonski M, Rigau V, Chemouny S, Taillandier L, Bauchet L, Duffau H, Paragios N.

PLoS One. 2016 Jan 11;11(1):e0144200. doi: 10.1371/journal.pone.0144200. eCollection 2016.

27.

Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K.

Lancet Haematol. 2015 Jun;2(6):e251-9. doi: 10.1016/S2352-3026(15)00074-5. Epub 2015 Jun 3.

PMID:
26688235
28.

Incidental diffuse low-grade gliomas: from early detection to preventive neuro-oncological surgery.

Lima GL, Zanello M, Mandonnet E, Taillandier L, Pallud J, Duffau H.

Neurosurg Rev. 2016 Jul;39(3):377-84. doi: 10.1007/s10143-015-0675-6. Epub 2015 Nov 27. Review.

PMID:
26610909
29.

Venous thrombosis in patients with high-grade glioma.

Taillibert S, Taillandier L, Le Rhun E.

Curr Opin Oncol. 2015 Nov;27(6):516-21. doi: 10.1097/CCO.0000000000000226. Review.

PMID:
26447877
30.

CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis.

Tu Q, Wu X, Le Rhun E, Blonski M, Wittwer B, Taillandier L, De Carvalho Bittencourt M, Faure GC.

Lung Cancer. 2015 Nov;90(2):352-7. doi: 10.1016/j.lungcan.2015.09.008. Epub 2015 Sep 14.

PMID:
26386833
31.

Correlation of SUV-Derived Indices With Tumoral Aggressiveness of Gliomas in Static 18F-FDOPA PET: Use in Clinical Practice.

Janvier L, Olivier P, Blonski M, Morel O, Vignaud JM, Karcher G, Taillandier L, Verger A.

Clin Nucl Med. 2015 Sep;40(9):e429-35. doi: 10.1097/RLU.0000000000000897.

PMID:
26204212
32.

Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006-2010.

Zouaoui S, Darlix A, Rigau V, Mathieu-Daudé H, Bauchet F, Bessaoud F, Fabbro-Peray P, Trétarre B, Figarella-Branger D, Taillandier L, Loiseau H, Bauchet L; French Brain Tumor DataBase (FBTDB) Participants and Investigators; with the participation of the Société française de neurochirurgie (SFNC); Club de neuro-oncologie de la SFNC; Société française de neuropathologie (SFNP); Association des neuro-oncologues d’expression française (ANOCEF).

Neurochirurgie. 2018 Mar;64(1):15-21. doi: 10.1016/j.neuchi.2014.11.013.

PMID:
26073920
33.

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P.

J Neurol. 2015 Jul;262(7):1637-45. doi: 10.1007/s00415-015-7758-8. Epub 2015 May 1.

PMID:
25929666
34.

[Editorial].

Taillandier L, Le Rhun É, Métellus P, Mornex F, Mazeron JJ.

Cancer Radiother. 2015 Feb;19(1):1-2. doi: 10.1016/j.canrad.2014.11.005. Epub 2015 Feb 7. French. No abstract available.

35.

[Supportive care, cognition and quality of life in brain metastases].

Le Rhun É, Taillibert S, Blonski M, Jouniaux Delbez N, Delgadillo D, Taillia H, Auquier P, Belin C, Bonnetain F, Varin D, Tallet A, Taillandier L.

Cancer Radiother. 2015 Feb;19(1):55-60. doi: 10.1016/j.canrad.2014.11.003. Epub 2015 Jan 29. Review. French.

PMID:
25640218
36.

Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France.

Darlix A, Zouaoui S, Virion JM, Rigau V, Mathieu-Daudé H, Blonski M, Reyes-Botero G, Bessaoud F, Trétarre B, Bauchet F, Capelle L, Fabbro M, Kerr C, Figarella-Branger D, Duffau H, Taillandier L, Bauchet L.

J Neurooncol. 2014 Dec;120(3):547-55. doi: 10.1007/s11060-014-1585-0. Epub 2014 Aug 24.

PMID:
25151505
37.

New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach.

Duffau H, Taillandier L.

Neuro Oncol. 2015 Mar;17(3):332-42. doi: 10.1093/neuonc/nou153. Epub 2014 Aug 2. Review.

38.

Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.

Karayan-Tapon L, Cortes U, Rivet P, Jermidi C, Vassal G, Wager M, Taillandier L.

Eur J Cancer. 2014 Sep;50(13):2364-6. doi: 10.1016/j.ejca.2014.06.001. Epub 2014 Jul 3. No abstract available.

PMID:
24999209
39.

A nonradiated grade II glioma that underwent delayed malignant transformation to a gliosarcoma with meningeal growth and dissemination.

Rech F, Rigau V, Fabbro M, Kerr C, Gauchotte G, Taillandier L, Duffau H.

J Neurol Surg A Cent Eur Neurosurg. 2014 Nov;75(6):485-90. doi: 10.1055/s-0034-1372437. Epub 2014 Jun 27.

PMID:
24971682
40.

[Supportive care, cognitive assessment and quality of life after treatment for brain metastases].

Le Rhun E, Taillandier L, Taillibert S.

Rev Prat. 2014 May;64(5):686-8. French. No abstract available.

PMID:
24923062
41.

Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

Gozé C, Blonski M, Le Maistre G, Bauchet L, Dezamis E, Page P, Varlet P, Capelle L, Devaux B, Taillandier L, Duffau H, Pallud J.

Neuro Oncol. 2014 Aug;16(8):1100-9. doi: 10.1093/neuonc/nou085. Epub 2014 May 20.

42.

Assessment and treatment relevance in elderly glioblastoma patients.

Bauchet L, Zouaoui S, Darlix A, Menjot de Champfleur N, Ferreira E, Fabbro M, Kerr C, Taillandier L.

Neuro Oncol. 2014 Nov;16(11):1459-68. doi: 10.1093/neuonc/nou063. Epub 2014 May 2. Review.

43.

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.

Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O.

Ann Oncol. 2014 Jul;25(7):1442-7. doi: 10.1093/annonc/mdu148. Epub 2014 Apr 9.

PMID:
24723487
44.

Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France.

Zouaoui S, Darlix A, Fabbro-Peray P, Mathieu-Daudé H, Rigau V, Fabbro M, Bessaoud F, Taillandier L, Ducray F, Bauchet F, Wager M, Faillot T, Capelle L, Loiseau H, Kerr C, Menei P, Duffau H, Figarella-Branger D, Chinot O, Trétarre B, Bauchet L.

Neurosurg Rev. 2014 Jul;37(3):415-23; discussion 423-4. doi: 10.1007/s10143-014-0528-8. Epub 2014 Feb 14.

PMID:
24526367
45.

Epileptic seizures in diffuse low-grade gliomas in adults.

Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, Mandonnet E, Dezamis E, Psimaras D, Guyotat J, Peruzzi P, Page P, Gal B, Párraga E, Baron MH, Vlaicu M, Guillevin R, Devaux B, Duffau H, Taillandier L, Capelle L, Huberfeld G.

Brain. 2014 Feb;137(Pt 2):449-62. doi: 10.1093/brain/awt345. Epub 2013 Dec 27.

PMID:
24374407
46.

Delayed leptomeningeal and subependymal seeding after multiple surgeries for supratentorial diffuse low-grade gliomas in adults.

Alvarez de Eulate-Beramendi S, Rigau V, Taillandier L, Duffau H.

J Neurosurg. 2014 Apr;120(4):833-9. doi: 10.3171/2013.10.JNS131512. Epub 2013 Nov 29.

PMID:
24286144
47.

The silent phase of diffuse low-grade gliomas. Is it when we missed the action?

Pallud J, Capelle L, Taillandier L, Badoual M, Duffau H, Mandonnet E.

Acta Neurochir (Wien). 2013 Dec;155(12):2237-42. doi: 10.1007/s00701-013-1886-7. Epub 2013 Oct 2.

PMID:
24085316
48.

Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.

Darlix A, Baumann C, Lorgis V, Ghiringhelli F, Blonski M, Chauffert B, Zouaoui S, Pinelli C, Rech F, Beauchesne P, Taillandier L.

Anticancer Res. 2013 Aug;33(8):3467-74.

PMID:
23898121
49.

Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.

Pinel S, Mriouah J, Vandamme M, Chateau A, Plénat F, Guérin E, Taillandier L, Bernier-Chastagner V, Merlin JL, Chastagner P.

PLoS One. 2013 Jul 18;8(7):e68333. doi: 10.1371/journal.pone.0068333. Print 2013.

50.

Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article.

Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, Pallud J, Peruzzi P, Baron MH, Kujas M, Guyotat J, Guillevin R, Frenay M, Taillibert S, Colin P, Rigau V, Vandenbos F, Pinelli C, Duffau H; French Réseau d'Étude des Gliomes.

J Neurosurg. 2013 Jun;118(6):1157-68. doi: 10.3171/2013.1.JNS121. Epub 2013 Mar 15.

PMID:
23495881

Supplemental Content

Loading ...
Support Center